http://orcid.org/0000-0002-4703-3534
References
- Gatta G, Capocaccia R, Trama A, et al. The burden of rare cancers in Europe. Adv Exp Med Biol. 2010;686:285–303.
- Gatta G, Trama A, Capocaccia R. RARECARENet Working Group Epidemiology of rare cancers and inequalities in oncologic outcomes. Eur J Surg Oncol. 2017 Sep 19. pii: S0748-7983(17)30685-6. doi: 10.1016/j.ejso.2017.08.018. [Epub ahead of print].
- [Cited 2018 Sep 22]. Available from: www.rarecancerseurope.org/
- Working to improve the management of sarcoma patients across Europe: a policy checklist. BMC Cancer. 2018 Apr 16;18(1):424.
- The European Parliament and the Council of the European Union. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Off J Eur Commun. 2000;43:1–5. OJ L 18(22.1.2000).
- Dockser Marcus A. To make progress in rare cancers, patients must lead the way. J Of Clin Oncol. 2009;27(16):2575-2577
- Pushparajah DS. Making patient engagement a reality. DOI:10.1007/s40271-017-0264-6
- [Cited 2018 Sep 22]. Available from: https://www.accrf.org
- [Cited 2018 Sep 22]. Available from: https://www.chordomafoundation.org
- Aymé S, Kole A, Groft S. Empowerment of patients: lessons from the rare diseases community. Lancet. 2008;371:2048–2051.
- EURORDIS, Rare Diseases Europe. Patients’ Priorities and Needs for Rare Disease Research 2014–2020.
- Ramsey BW, Nepom GT, Lonial S. Academic, foundation, and industry collaboration in finding new therapies. N Engl J Med. 2017 May 4;376: 1762–1769. .
- P Kanavos, R Sullivan, Lewison G, et al. The role of funding and policies on innovation in cancer drug development. Ecancermedicalscience. 2010;4:164.
- Wagstaff A. A breakthrough business model for drug development Cancerworld March/April 2017, 56–63
- [Cited 2018 Sep 22]. Available from: http://www.eupati.eu
- EMA/CHMP/292464/2014. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies. April 2016
- Involvement of patient representatives in scientific advice procedures at EMA, 10 January 2017, EMA/736615/2013 Rev 2
- The Committee for Orphan Medicinal Products and the European Medicines Agency Scientific Secretariat. European regulation on orphan medicinal products. 10 years of experience and future perspectives. Nat Rev Drug Discov. 2011;10:341.
- 21st Century Cures Act PUBLIC LAW 114–255—DEC. 13, 2016
- Mattingly JT, Simoni-Wastila L. Patient-centered drug approval: the role of patient advocacy in the drug approval process. J Manag Care Specialty Pharm JMCP. 2017;23(10):1078-1082
- Liberti L, Stolk P, McAuslane N et al. Adaptive Licensing and Facilitated Regulatory Pathways: A Survey of Stakeholder Perceptions Clinical Pharmacology & Therapeutics, Vol. 98 5 November 2015
- EMA Adaptive Pathways. [Cited 2018 Sep 22]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general/content/000601.jsp&mid=WC0b01ac05807d58ce.
- Gonzato O. The new risk-sharing paradigm in rare cancers: patient perspective. J Cancer Policy. 2017;12:36–42.
- Regulation 1901/2006/EC of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric Use. [Cited 2018 Sep 22]. Available from: http://ec.europa.eu/health//sites/health/files/files/eudralex/vol1/reg/2006/1901en.pdf.
- Sarcoma patient pathway analysis and recommendations for service development, SPAEN Sarcoma Policy Paper, 2016
- Andritscha E, Beishonb M, Bielackc S, et al. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. In: Critical Reviews in Oncology/Hematology, 2017;110:94–105.